;
Skip to main content
Home > Week in Review > Management

Chronological Index of : Management Tracks

 Current Issue
  • Abcam management update

    Abcam plc (LSE:ABC), Cambridge, U.K. Business: Antibodies Transitioned: Alan Hirzel to CEO from CMO, while remaining a director; he succeeds Jonathan Milner, who becomes deputy chairman

    Published on 9/15/2014
  • Acucela management update

    Acucela Inc. (Tokyo:4589), Seattle, Wash. Business: Ophthalmic Departed: David Lowrance as CFO Hired: Brian O'Callaghan, a director, as president and COO,a newly created role, and interim CFO, formerly CEO and chairman …

    Published on 9/15/2014
  • Afferent management update

    Afferent Pharmaceuticals Inc., San Mateo, Calif. Business: Neurology Hired: Kathleen Sereda Glaub, a director, as CEO, formerly president at Plexxikon Inc., which Daiichi Sankyo Co. Ltd. acquired; she succeeds Bruce …

    Published on 9/15/2014
  • Affiris management update

    Affiris AG, Vienna, Austria Business: Neurology, Cardiovascular, inflammation Hired: Oliver Siegel as COO, formerly Head of European pharmaceutical sector at Edmond de Rothschild Investment Partners

    Published on 9/15/2014
  • Agilis Biotherapeutics management update

    Agilis Biotherapeutics LLC, Germantown, Md. Business: Neurology, Gene/Cell therapy Hired: Mark Pykett as president and CEO, formerly president and CEO of Navidea Biopharmaceuticals Inc.

    Published on 9/15/2014
  • AM-Pharma board of directors update

    AM-Pharma B.V., Bunnik, the Netherlands Business: Renal, Autoimmune Appointed: Edwin de Graaf, managing director at Gilde Healthcare Partners

    Published on 9/15/2014
  • Aptose Biosciences management update

    Aptose Biosciences Inc. (TSX:APS; Pink:APSCF), Toronto, Ontario Business: Cancer, Gene/Cell therapy Hired: Stephen Howell as acting CMO, currently a professor at the University of California, San Diego

    Published on 9/15/2014
  • Ardelyx management update

    Ardelyx Inc. (NASDAQ:ARDX), Fremont, Calif. Business: Gastrointestinal, Renal, Endocrine/Metabolic Retiring: Dominique Charmot as CSO, effective Dec. 23

    Published on 9/15/2014
  • Batu Biologics management update

    Batu Biologics Inc., San Diego, Calif. Business: Cancer Hired: Hong Ma as CSO

    Published on 9/15/2014
  • Catalyst Pharma management update

    Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla. Business: Neurology Hired: David Muth as EVP of corporate development, a newly created position, formerly president and CEO of the Croma …

    Published on 9/15/2014
  • diaDexus management update

    diaDexus Inc. (OTCBB:DDXS), South San Francisco, Calif. Business: Diagnostic Resigning: Jean Viret as CFO, effective Sept. 19

    Published on 9/15/2014
  • Ignyta management update

    Ignyta Inc. (NASDAQ:RXDX), San Diego, Calif. Business: Cancer, Diagnostic Hired: Robert Wild as SVP of research and CSO, formerly CSO of oncology research and drug discovery at Eli Lilly and Co.; he succeeds Patrick O'…

    Published on 9/15/2014
  • LLS management update

    The Leukemia & Lymphoma Society (LLS), White Plains, N.Y. Business: Cancer Transitioned: Louis DeGennaro to president and CEO from interim president and CEO

    Published on 9/15/2014
  • Medgenics management update

    Medgenics Inc. (NYSE-M:MDGN), Vienna, Va. Business: Gene/Cell therapy, Drug delivery Hired: Scott Applebaum as chief legal officer, formerly SVP of the neuroscience business unit at Shire plc

    Published on 9/15/2014
  • Novimmune management update

    Novimmune S.A., Plan-les-Ouates, Switzerland Business: Autoimmune, Inflammation, Transplant Departing: David Slack as head of corporate and business development Hired: Adrian Mills as CBO, formerly European commercial …

    Published on 9/15/2014
  • Pivotal Therapeutics management update

    Pivotal Therapeutics Inc. (CNSX:PVO; OTCQX:PVTTF), Woodbridge, Ontario Business: Cardiovascular Hired: Prakash Gowd as CFO; he succeeds Eugene Bortoluzzi, who remains CEO and a director

    Published on 9/15/2014
  • ReNeuron management update

    ReNeuron Group plc (LSE:RENE), Guildford, U.K. Business: Neurology Hired: Olav Hellebo as CEO; he succeeds Michael Hunt, who remains CFO

    Published on 9/15/2014
  • to-BBB management update

    to-BBB technologies B.V., Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Hired: Anders Harfstrand as CEO, formerly president and CEO of Humabs BioMed S.A.; he succeeds interim CEO Leonard Kruimer, …

    Published on 9/15/2014
  • Venter Institute management update

    J. Craig Venter Institute, Rockville, Md. Business: Genomics Hired: Nicole DeBerg as COO, formerly CFO of Sanford-Burnham Medical Research Institute

    Published on 9/15/2014
  • Apotex management update

    Apotex Inc., Toronto, Ontario Business: Generics, Biosimilars Transitioned: Jeremy Desai to CEO from COO, while remaining president; he succeeds Jack Kay, who becomes vice chairman

    Published on 9/8/2014
  • Atossa Genetics management update

    Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash. Business: Diagnostic Hired: Scott Youmans as SVP of operations, formerly director of development of the Precision Olfactory Delivery Device at Impel NeuroPharma Inc.; …

    Published on 9/8/2014
  • BioNTech management update

    BioNTech AG, Mainz, Germany Business: Cancer, Diagnostic Hired: Sierk Potting as CFO, formerly CFO and VP of Novartis AG's Sandoz Inc. generics unit; he succeeds Michael Kring, who remains a director

    Published on 9/8/2014
  • Cerenis board of directors update

    Cerenis Therapeutics S.A., Labege, France Business: Cardiovascular, Endocrine/Metabolic Appointed: Richard Pasternak, a director, as chairman; he succeeds Jean-Pierre Garnier

    Published on 9/8/2014
  • Chimerix management update

    Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. Business: Infectious Hired: Garrett Nichols as CMO, formerly head of global development at ViiV Healthcare Ltd.

    Published on 9/8/2014
  • Epizyme management update

    Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. Business: Cancer Resigning: Jason Rhodes as president and CFO, effective Sept. 30; he will join an undisclosed VC

    Published on 9/8/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993